Latest news with #Progyny
Yahoo
5 days ago
- Business
- Yahoo
Why Progyny (PGNY) Stock Is Falling Today
What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) fell 3.9% in the afternoon session after a regulatory filing revealed a significant institutional investor had sharply reduced its stake in the company. The fertility and family-building benefits company saw its shares trade lower after a Form 13F filing, reported Friday, disclosed that investment firm Edgestream Partners L.P. had sold 105,195 shares. This sale represented a 56.4% reduction in the firm's position during the first quarter. A 13F is a quarterly report filed by institutional investment managers with over $100 million in assets under management to declare their U.S. equity holdings. While the sale occurred in a prior quarter, the release of the filing can influence current investor sentiment. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Progyny? Access our full analysis report here, it's free. What Is The Market Telling Us Progyny's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Progyny is up 24.2% since the beginning of the year, but at $22.02 per share, it is still trading 24.4% below its 52-week high of $29.14 from July 2024. Investors who bought $1,000 worth of Progyny's shares 5 years ago would now be looking at an investment worth $843.68. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Health
- Yahoo
Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA, maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging members upstream as they are being more proactive with their health. As a result, potential risks can be identified earlier, while also supporting a range of health goals, such as optimizing conception attempts or making sustainable lifestyle changes. 'The more women understand about their bodies, the more empowered they are to partner with their health providers and articulate their health status and goals. Whether you are focused on conceiving your first child or managing changing weight and sleep issues through menopause, understanding your personal data is powerful—physically and emotionally,' said Janet Choi, MD, Progyny Chief Medical Officer. 'Taking control with physiologic data from the Oura Ring further supports Progyny's focus on raising the bar and elevating health outcomes.' With the ability to continuously track key health metrics, such as sleep patterns, cycle insights, cardiovascular health, stress levels, and more, ŌURA helps women understand their bodies so they can achieve optimal health. For those trying to conceive, these insights can help pinpoint fertile windows and support reproductive planning. During perimenopause or menopause, they can help identify patterns, guide impactful lifestyle adjustments, and inform meaningful conversations with providers. When needed, care plans, including personalized recommendations around sleep, nutrition, movement, and stress to support the body's changing needs can be developed. 'Reproductive health management starts long before a doctor's visit—it begins with daily awareness of your body's patterns,' said Dorothy Kilroy, Chief Commercial Officer at ŌURA. 'By partnering with Progyny, we're bridging the gap between those daily health patterns and clinical care, helping people navigate fertility and family planning with greater clarity, confidence, and support. This collaboration brings Oura's powerful health signals into a setting where they can truly make a difference—guiding smarter care, earlier interventions, and more personalized journeys.' Oura Ring and Oura Membership will be available to Progyny clients, including employers and health plans, beginning in early 2026. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For More Information, Please Contact: Media:Alexis Fordmedia@ Investors:James Hartinvestors@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Globe and Mail
08-07-2025
- Business
- Globe and Mail
Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report
Operational and Financial Flexibility Enhanced Through New Credit Facility Second Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) ('Progyny' or the 'Company'), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the 'revolver' or the 'facility') which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expected to enhance the Company's operational and financial flexibility beyond its current ability to generate significant cash flow. 'At this stage of our growth, entering into a facility is an appropriate next step to further enhance our strong financial profile and extend our market leadership, and with the favorable market conditions, we felt this was an opportune time for us to transact,' said Pete Anevski, Chief Executive Officer of Progyny. The revolver is undrawn, and the Company has no planned use for the facility at this time. The Company's capital priorities, which include the evaluation of stock repurchases, the expansion of its product portfolio, investments in new distribution channels, and select acquisitions, remain unchanged. The Company also announced today that it expects its financial results for the quarterly period ending June 30, 2025, to be slightly better than the guidance ranges it provided during its first quarter earnings call. 'As the second quarter progressed, we were pleased to see that member activity has paced favorably as compared to our guidance,' continued Anevski. 'Accordingly, we now expect second quarter results for revenue, Adjusted net income and Adjusted EBITDA to be slightly above the ranges that we provided in May.' The company will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Thursday, August 7, 2025. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An audio replay of the call will be available through Thursday, August 14, 2025, and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484. A live webcast and archive of the call will be available from the Events and Presentations section of the company's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain's Fast 50 for NYC. For more information, visit Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our financial outlook for the second quarter and full year 2025, including the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2025; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2026 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words 'anticipates,' 'assumes,' 'believe,' 'contemplate,' 'continues, ' 'could,' 'estimates,' 'expects,' 'future,' 'intends,' 'may,' 'plans,' 'predict,' 'potential,' 'project,' 'seeks,' 'should,' 'target,' 'will,' and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the 'SEC'), including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent reports that we file with the SEC, which are available at and on the SEC's website at Forward-looking statements represent our management's beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons. Non-GAAP Financial Measures In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ('GAAP'), this press release includes the non-GAAP financial measure Adjusted EBITDA. Adjusted EBITDA is a supplemental financial measure that is not required by, or presented in accordance with, GAAP. We believe that this non-GAAP measure, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA is helpful to our investors as it is used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes. Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating income and expenses, including interest and other income, net; and (5) it does not reflect tax payments that may represent a reduction in cash available to us. In addition, Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate such measures in the same manner as we calculate Adjusted EBITDA, limiting its usefulness as a comparative measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net income and our other GAAP results. We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; interest and other income, net; and provision for income taxes.
Forbes
17-06-2025
- Business
- Forbes
Companies Need To Modernize Their Parental Leave Policies
Cynthia McEwen is the Vice President of People at women's health benefits company Progyny. According to a 2023 U.S. Office of the Surgeon General Advisory, nearly 50% of parents said they experienced overwhelming stress most days. But when it comes to employer-provided support, such as parental leave policies, many modern workplaces aren't offering what these caregivers need. Traditional leave policies often fail to account for the wide range of family structures and birth-related situations that exist today. Adaptable parental leave policies are more than a benefit. They're a strategic imperative for employers seeking to attract and retain talent. Let's examine these challenges and determine how employers can effectively address them, ensuring both employee support and a strong bottom line. Caregivers who adopt or foster children face unique challenges. For example, the legal processes involved in pursuing this path require extensive preparation, including up to six months of in-person appointments that often take place during business hours. International adoptions present additional challenges, like extensive travel and even more complex legal procedures, that don't always align with conventional leave timeframes. Meanwhile, foster placements often occur at a pace that makes it impractical to adhere to standard leave policies' advanced notice requirements. Companies can alleviate these challenges by offering more flexible parental leave policies that accommodate home studies and training, travel and last-minute placements in fostering households. Other useful support for easing the transition to parenthood are financial assistance for adoption-related expenses, access to counseling and parent-focused employee resource groups. Birth complications highlight the additional inadequacy of many parental leave policies. According to a 2023 study on maternal health, women are still at risk for developing serious health conditions after the standard postpartum period of six to eight weeks. These may result in extended recovery periods, frequent medical follow-ups and a need for additional caregiving support. Meanwhile, the non-birthing parent must be able to provide the necessary emotional and logistical support. However, many postpartum care services end after six weeks, leaving parents without the resources they need. Supporting employees through birth complications requires a multifaceted approach. Return-to-work assistance, for example, helps reduce absenteeism, improve retention and mitigate long-term career setbacks. Offering extended leave or flexible work arrangements for employees whose partner is in postpartum recovery can help improve health outcomes for both parents and reduce stress during an already challenging time. Additionally, benefits must go beyond medical care. Mental health support, such as access to employee assistance programs, is particularly vital because psychological distress is a significant factor in maternal morbidity and mortality. By addressing both medical and emotional needs, employers can foster a more supportive environment for all parents affected by birth complications. In many cultures, childbirth is a communal experience where extended family plays a major role in postpartum care. Parental leave policies that fail to consider these cultural norms may force employees to choose between their professional responsibilities and deeply rooted traditions that support maternal and family well-being. By accommodating cultural birth-related practices—whether through adequate paid leave, flexible return-to-work options or childcare-related resources—companies can demonstrate respect for all parents. There are many family structures beyond the stereotypical two-parent household, such as single-parent households, blended families and families formed through surrogacy. But traditional parental leave policies rarely address these families' specific circumstances. For example, if a single parent is responsible for all caregiving duties, they may have greater time off needs than someone with a co-parent or a strong support system. Parents with blended families may need flexibility to accommodate legal arrangements, while families formed through surrogacy often need additional time for the emotional adjustments associated with welcoming a child. When companies provide parental leave, they should consider all paths to parenthood and different ways that families form. Policies that are paired with back-to-work transition support, new-parent educational resources and other tools help create a workplace culture where individuals can thrive both professionally and personally. As we continue to redefine what it means to "work well," let's ensure parental leave policies evolve to meet the needs of today's workforce. Anything less risks perpetuating inequities and forfeits the opportunity to build truly empowering workplaces. Forbes Human Resources Council is an invitation-only organization for HR executives across all industries. Do I qualify?
Yahoo
29-05-2025
- Business
- Yahoo
Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors. "As we continue to round out our board's experience, Elizabeth's extensive leadership with some of the largest health plans and deep financial expertise will be invaluable as we scale and innovate across the women's health and family building spectrum," said Pete Anevski, CEO of Progyny. "Her insights will support our strategy to deliver even more value to our members, clients, and shareholders as we expand our reach and impact." Bierbower brings more than 30 years of experience in the healthcare industry, having held leadership roles across health plans, provider services, and care innovation. She most recently served as Chairman and CEO of Friday Health Plans and held various senior positions at Humana, including Segment President, President of the Employer Group Segment, and Chief Operating Officer of the Specialty Benefits division. Prior to Humana, she held leadership roles at Highmark Blue Cross Blue Shield and Coventry Health Care. Bierbower's depth of healthcare experience also includes serving on the board of directors of numerous companies including Option Care Health, the largest national independent provider for infusion therapy, as well as the boards of several privately held companies, including BlueSprig, Quest Analytics, Paradigm Corp., and Point32Health. 'Progyny is setting the standard for what comprehensive, outcomes-based women's health and family building benefits should look like in today's workforce,' said Bierbower. 'I'm joining the board at an exciting time as the company continues its expansion of both products and reach, and I look forward to contributing to the team's objective of advancing access to high-quality care for women and families.' For more information about Progyny and its Board of Directors, please visit About ProgynyProgyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact: Investors:James Hartinvestors@ Media:Alexis Fordmedia@ in to access your portfolio
